U.S. Food and Drug Administration (FDA) has approved Zioptan
(tafluprost ophthalmic solution) 0.0015%, the first preservative-free
prostaglandin analog ophthalmic solution. Zioptan (pronounced
zye-OP-tan) is approved for reducing elevated intraocular pressure (IOP)
in patients with open-angle glaucoma (OAG) or ocular hypertension.
Open-angle glaucoma is the most common form of glaucoma, while ocular
hypertension is a condition characterized by an increase in pressure
inside the eye.
Ref : http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2012_0213.html
